Program
zenagamtide
Also written as “NNC0487-0111”, “Zenagamtide” and “NNC0487-0111 A”.
In Novo Nordisk’s own words, Zenagamtide is the first of its class, being a unimolecular peptide agonist of GLP-1 and amylin receptors.
. Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Diabetes Mellitus, led by Novo Nordisk.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordisk | 3627 open or running | phase 3since Jan 13, 2026 | May 4, 2022 | Nov 11, 2027phase 1 · NCT07535307 |
- Named in Novo Nordisk’s own pipeline as
Zenagamtide (sc and oral)
, phase 3, as of Nov 5, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 11 earlier studies, May 4, 2022 to Feb 3, 2026.
- Jul 10, 2025Named zenagamtideINNProposed as its International Nonproprietary Name in WHO's List 133 · before, NNC0487-0111
- Mar 13, 20263 phase 3 studies in ObesityNCT07481630, NCT07503210, NCT07509307
- Mar 27, 2026Phase 1 study in ObesityNCT07508020 · 120 planned · Germany
- Apr 9, 2026Phase 1 study in Diabetes MellitusNCT07535307 · 80 planned · Germany
- Apr 9, 20264 phase 3 studiesNCT07533175, NCT07567001, NCT07571109 and 1 more
- May 8, 2026Phase 1 study in OverweightNCT07587710 · 35 planned · Slovakia
- Jun 18, 20262 phase 3 studiesNCT07668401, NCT07668414
- Jul 17, 2026Phase 3 study in OverweightNCT07720271 · 950 planned · United States
- Jul 30, 2026Phase 1 study in OverweightNCT07757087 · 120 planned · Denmark, Netherlands
- Aug 26, 2026Phase 3 study in Diabetes Mellitus, Type 2NCT07797335 · 1,778 planned · United States, Argentina, Brazil and more
- Sep 6, 20262 phase 1 studies in OverweightNCT07815067, NCT07855133
- Sep 10, 20262 phase 3 studiesNCT07822061, NCT07861100
- Oct 5, 2026Phase 1 study in OverweightNCT07868354 · 60 planned · United States
- Nov 6, 20264 phase 3 studies in Diabetes Mellitus, Type 2NCT07931599, NCT07931573, NCT07931547 and 1 more
- Nov 11, 2026Phase 1 study in OverweightNCT07944118 · 36 planned · United States
Ahead
- Nov 11, 2027Primary completion: phase 1 study in Diabetes MellitusNCT07535307
- Dec 1, 2027Primary completion: phase 1 study in OverweightNCT07587710
- Jan 14, 2028Primary completion: phase 1 study in OverweightNCT07944118
- Jan 19, 2028Primary completion: phase 1 study in ObesityNCT07508020
TargetBeta
“Zenagamtide is the first of its class, being a unimolecular peptide agonist of GLP-1 and amylin receptors.”company, read by Claude · source
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| CagriSema A | Novo Nordisk | phase 1 | 1 |
Studies
All 36 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07944118Overweight · United States | 1 | Not yet recruiting | Jan 14, 2028 | 36 |
| NCT07931599Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more | 3 | Not yet recruiting | Jul 24, 2028 | 1,060 |
| NCT07931573Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more | 3 | Not yet recruiting | Jul 4, 2028 | 1,200 |
| NCT07931547Diabetes Mellitus, Type 2 · United States, Brazil, China and more | 3 | Not yet recruiting | Jul 31, 2028 | 450 |
| NCT07931495Diabetes Mellitus, Type 2 · United States, China, Japan and more | 3 | Not yet recruiting | Jun 5, 2028 | 200 |
| NCT07868354Overweight · United States | 1 | Recruiting | Sep 7, 2028 | 60 |
| NCT07861100Obesity · United States, Argentina, Australia and more | 3 | Not yet recruiting | Sep 16, 2030 | 8,500 |
| NCT07855133Overweight · United States | 1 | Recruiting | Sep 6, 2028 | 60 |
| NCT07822061Overweight · Japan | 3 | Recruiting | Feb 5, 2029 | 400 |
| NCT07815067Overweight · Germany | 1 | Recruiting | Jun 12, 2028 | 320 |
| NCT07797335Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more | 3 | Recruiting | Jul 31, 2028 | 1,778 |
| NCT07757087Overweight · Denmark, Netherlands | 1 | Recruiting | Sep 18, 2028 | 120 |
| NCT07720271Overweight · United States | 3 | Recruiting | Jun 27, 2028 | 950 |
| NCT07668414Overweight · United States | 3 | Recruiting | Oct 10, 2028 | 650 |
| NCT07668401Obesity · India, Japan, Malaysia and more | 3 | Not yet recruiting | Jan 11, 2029 | 400 |
| NCT07587710Overweight · Slovakia | 1 | Recruiting | Dec 1, 2027 | 35 |
| NCT07571109Obesity · United States, Australia, China and more | 3 | Recruiting | Jun 26, 2028 | 300 |
| NCT07571005Obesity · United States, Australia, China and more | 3 | Recruiting | Jul 12, 2028 | 300 |
| NCT07567001Obesity · United States, Argentina, Australia and more | 3 | Recruiting | Jul 23, 2029 | 5,610 |
| NCT07535307Diabetes Mellitus · Germany | 1 | Recruiting | Nov 11, 2027 | 80 |
| NCT07533175Diabetes Mellitus · United States, Argentina, Brazil and more | 3 | Active, not recruiting | Aug 7, 2028 | 638 |
| NCT07509307Obesity · United States, Australia, Bulgaria and more | 3 | Recruiting | Aug 14, 2028 | 400 |
| NCT07508020Obesity · Germany | 1 | Recruiting | Jan 19, 2028 | 120 |
| NCT07503210Obesity · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jun 6, 2028 | 606 |
| NCT07481630Obesity · United States, Australia, Bulgaria and more | 3 | Recruiting | Aug 14, 2028 | 400 |
| NCT07400107Obesity · United States, Argentina, Brazil and more | 3 | Active, not recruiting | Dec 19, 2028 | 985 |
| NCT07339423Obesity · United States, Argentina, Australia and more | 3 | Recruiting | Jun 26, 2029 | 1,150 |
| NCT07121153Overweight · China | 1 | Completed | Dec 20, 2025 | 36 |
| NCT06820476Overweight · China | 1 | Completed | May 14, 2025 | 29 |
| NCT06559527Diabetes Mellitus, Type 2 · Germany | 1 | Completed | Feb 24, 2025 | 42 |
| NCT06542874Diabetes Mellitus, Type 2 · United States, Bulgaria, Croatia and more | 2 | Completed | Oct 1, 2025 | 448 |
| NCT06478563Obesity · United States | 1 | Completed | Jun 5, 2025 | 133 |
| NCT06461039Obesity · Canada | 1 | Completed | Mar 16, 2025 | 43 |
| NCT06064006Obesity · United States | 2 | Completed | Nov 27, 2024 | 125 |
| NCT06049329Obesity · Japan | 1 | Completed | Dec 15, 2023 | 36 |
| NCT05369390Obesity · United States | 1 | Completed | Jan 9, 2024 | 144 |
How it is read
Names in the registry
- “NNC0487-0111”, 18 entries
- “Zenagamtide”, 11 entries
- “NNC0487-0111 A”, 3 entries
- “Zenagamtide injection”, 1 entry
- “Zenagamtide tablet”, 1 entry
Codes read as this program: NNC04870111.
Conditions, from the studies’ own filings
- Obesity, 27 studies
- Diabetes Mellitus, Type 2, 7 studies
- Diabetes Mellitus, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.